Dynavax Technologies (DVAX)
(Real Time Quote from BATS)
$11.80 USD
-0.08 (-0.67%)
Updated May 23, 2024 11:10 AM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Dynavax Technologies Corporation [DVAX]
Reports for Purchase
Showing records 1 - 20 ( 121 total )
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
4Q23 Results; 2024 Heplisav-B Sales Guidance Range Above Our Prior Estimate; Raising PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
2023 Heplisav-B Sales Within Guidance but Below Expectations; Several Potential Pipeline Catalysts For the Stock in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for DVAX 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
3Q23 Results; Heplisav-B Sales Continue to Impress, Raising Estimates and Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Recap of Dynavax at the H.C. Wainwright Annual Hepatitis B Virus Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
2Q23 Results; Another Quarter of Record Heplisav-B Sales, Guidance Raised
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
1Q23 Results; Impressive Heplisav-B Sales Exceed Expectations
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
4Q22 Results; Record Annual Heplisav-B Sales; Lowering PT by $1 Due to Lower CpG 1018 Estimates
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Preliminary FY22 Commercial and Financial Highlights
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
3Q22 Results; Heplisav-B Continues to Take Share; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Recap of Dynavax at the H.C. Wainwright Annual Hepatitis B Virus Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
2Q22 Results; 2Q Revenues Exceeded Expectations; Record Revenues Expected for Both Products in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
1Q22 Results; Heplisav-B Continues to Gain Market Share; CpG 1018 FY22 Guidance Remains at Over $550 Million in Sales
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
European Regulatory Update For VLA2001 COVID-19 Vaccine Adjuvanted With Dynavax''s CpG 1018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
VLA2001 COVID-19 Vaccine Adjuvanted With Dynavax''s CpG 1018 Receives Conditional Marketing Authorization in the U.K.
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
4Q21 Results; Solid Growth for Heplisav-B Expected to Continue and CpG 1018 Guidance for 2022 Above Our Expectations
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
2022 Strategic Priorities; Phase 1 Shingles Study Initiated
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E